FY2027 EPS Forecast for Zevra Therapeutics Raised by Analyst

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – HC Wainwright raised their FY2027 earnings per share (EPS) estimates for shares of Zevra Therapeutics in a research note issued to investors on Thursday, August 6th. HC Wainwright analyst B. Folkes now forecasts that the company will post earnings per share of $0.55 for the year, up from their previous estimate of $0.46. HC Wainwright currently has a “Buy” rating and a $26.00 target price on the stock. The consensus estimate for Zevra Therapeutics’ current full-year earnings is $0.60 per share. HC Wainwright also issued estimates for Zevra Therapeutics’ FY2028 earnings at $0.61 EPS, FY2029 earnings at $1.13 EPS and FY2030 earnings at $1.69 EPS.

ZVRA has been the subject of several other research reports. Citigroup restated an “outperform” rating on shares of Zevra Therapeutics in a research report on Thursday. Weiss Ratings cut Zevra Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a research note on Friday, May 22nd. Citizens Jmp raised their price target on Zevra Therapeutics from $25.00 to $28.00 and gave the stock a “market outperform” rating in a research report on Thursday, August 6th. Guggenheim reduced their target price on shares of Zevra Therapeutics from $24.00 to $23.00 and set a “buy” rating for the company in a research note on Friday. Finally, BTIG Research lowered their price objective on shares of Zevra Therapeutics from $27.00 to $24.00 and set a “buy” rating on the stock in a report on Monday, July 27th. Nine research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $27.14.

Zevra Therapeutics Stock Down 0.7%

Shares of ZVRA opened at $11.48 on Monday. The stock has a market cap of $681.68 million, a price-to-earnings ratio of 12.48 and a beta of 0.91. The company has a 50-day moving average price of $12.32 and a two-hundred day moving average price of $10.60. Zevra Therapeutics has a 12 month low of $7.16 and a 12 month high of $15.03.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its earnings results on Wednesday, August 5th. The company reported $0.25 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.14. The business had revenue of $39.66 million for the quarter, compared to analyst estimates of $33.88 million. Zevra Therapeutics had a net margin of 42.82% and a return on equity of 54.54%.

Institutional Trading of Zevra Therapeutics

Several large investors have recently modified their holdings of the stock. Adage Capital Partners GP L.L.C. lifted its stake in shares of Zevra Therapeutics by 15.2% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 4,168,000 shares of the company’s stock valued at $36,720,000 after acquiring an additional 550,000 shares during the last quarter. Vanguard Group Inc. grew its position in Zevra Therapeutics by 4.4% during the 3rd quarter. Vanguard Group Inc. now owns 3,083,362 shares of the company’s stock worth $29,323,000 after acquiring an additional 130,676 shares during the last quarter. Nantahala Capital Management LLC grew its position in Zevra Therapeutics by 34.0% during the 3rd quarter. Nantahala Capital Management LLC now owns 1,971,936 shares of the company’s stock worth $18,753,000 after acquiring an additional 500,000 shares during the last quarter. Rubric Capital Management LP increased its holdings in Zevra Therapeutics by 60.8% in the 2nd quarter. Rubric Capital Management LP now owns 1,958,318 shares of the company’s stock worth $17,253,000 after purchasing an additional 740,584 shares in the last quarter. Finally, State Street Corp increased its holdings in Zevra Therapeutics by 3.9% in the 4th quarter. State Street Corp now owns 1,482,956 shares of the company’s stock worth $13,287,000 after purchasing an additional 55,665 shares in the last quarter. 35.03% of the stock is owned by institutional investors and hedge funds.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.